期刊文献+

马尼地平栓的制备及质量评价

Preparation and Quality Evaluation of Manidipine Suppositories
原文传递
导出
摘要 目的:制备马尼地平(MNDP)栓,并对其进行质量评价。方法:以成型性等指标筛选甘油明胶等栓剂基质;将MNDP制成固体分散体后再制成栓剂;加入表面活性剂以提高栓剂溶出并采用正交试验筛选表面活性剂的最佳处方;测定并比较3种栓剂(甘油明胶、固体分散体、加入表面活性剂)的累积溶出度。结果:筛选出以甘油明胶为栓剂的基质,表面活性剂的最佳处方为吐温801%,泊洛沙姆2.50%,十二烷基磺酸钠0.125%,聚乙二醇400010%。3种栓剂8h时MNDP的累积溶出度分别为25%、44%、60%;优化后栓剂24h时MNDP的累积溶出度达到90%以上。结论:MNDP固体分散体能明显增加主药的体外溶出,加入表面活性剂可进一步增加药物的溶出,优选出最佳处方后制得的3批栓剂质量均符合要求。 OBJECTIVE: To prepare Manidipine (MNDP) suppositories, and to evaluate the quality of them. METHODS: Glycerogelatin and other suppositories matrixes were screened by moldability index and other indexes; MNDP was made into solid dispersion to obtain suppository; surfactants were added to increase dissolution rate of MNDP, and orthogonal design was adopted to screen the optimal formula of Manidipine suppositories; accumulative dissolution rates of 3 kinds of suppositories (glycerogela- tin, solid dispersion and surfactants added) were determined and compared. RESULTS: Glycerogelatin was used as matrix, and the optimal formula of surfactant was 1% Tween-80, 2.50% poloxamer, 0.125% SDS and 10% PEG4000. Accumulative dissolution rates of MNDP of 3 kinds of suppositories within 8 h can reach 25%, 44% and 60% ; accumulative dissolution rates of MNDP of optimized suppository was 90% above in 24 h. CONCLUSIONS: MNDP solid dispersion can obviously improve the dissolution of MNDP in vitro. Surfactants added can further improve dissolution rate. 3 batches of suppositories prepared by optimized formula all meet with the quality requirements.
出处 《中国药房》 CAS CSCD 2012年第25期2361-2364,共4页 China Pharmacy
关键词 马尼地平 栓剂 制备 质量评价 固体分散体 热熔法 溶出度 Manidipine Suppositories Preparation Quality evaluation Solid dispersion Melting method Dissolution rate
  • 相关文献

参考文献4

二级参考文献24

  • 1唐春仕.高血压病的预防及治疗策略[J].内科,2007,2(3):421-423. 被引量:15
  • 2[1]DHEIN S, SALAMEH A, BERKELS R, et al. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide[J]. Drugs, 1999, 58(3):397-404.
  • 3[2]Anon. The sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure[J]. Arch Intern Med, 1997, 157(21):2413-2446.
  • 4[3]LUSCHER TF, COSENTINO F. The classification of calcium antagonists and their selection in the treatment of hypertension: a reappraisal[J]. Drugs, 1998, 55(4):509-517.
  • 5[4]OKABE K, TERADA K, KITAMURA K, et al. Selective and long-lasting inhibitory action of the dihydropyridine derivative, CV-4093, on calcium currents in smooth muscle cells of the rabbit pulmonary artery[J]. J Pharmacol Exp Ther, 1987, 243(2):703-710.
  • 6[5]CHEER SM, MCCLELLAN K. Manidipine: a review of its use in hypertension[J]. Drugs, 2001, 61(12):1777-1799.
  • 7[6]PFAFFENDORF M, MATHY MJ, van ZWIETEN PA. Effects of manidipine and other calcium antagonists on rat renal arcuate arteries[J]. Am Heart J, 1993, 125(2 Pt 2): 571-577.
  • 8[7]FOGARI R, ZOPPI A, MUGELLINI A, et al. Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives[J]. Cardiovasc Drugs Ther, 1999, 13(3):243-248.
  • 9[8]MANCIA G, OMBONI S, AGABITI-ROSEI E, et al. Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients[J]. J Cardiovas Pharmacol, 2000, 35(6):926-931.
  • 10[9]HASE MI, HASE O, IGAWA S, et al. Reduction of left ventricular mass by manidipine hydrochloride[J]. Am J Hypertens, 1998, 11(4 Pt 2):81A.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部